Clinigen FY underlying earnings impacted by decrease in products revenue
9th Jun 2021 09:07
(Sharecast News) - Pharmaceutical firm Clinigen said on Wednesday that while net revenues were still expected to be in line with both guidance and expectations, full-year adjusted underlying earnings were now projected to be within the range of £114.0m and £117.0m due to a decrease in revenues from its products division.
Read moreTuesday broker round-up
6th Apr 2021 13:27
(Sharecast News) - Touchstone Exploration: Canaccord downgrades to speculative buy with a target price of 140p.
Read moreClinigen to launch 'Erwinase' in the UK earlier than planned
6th Apr 2021 08:37
(Sharecast News) - Pharmaceutical products and services company Clinigen Group announced on Tuesday that it will be providing access to 'Erwinase', or L-asparaginase Erwinia chrysanthemi, in the UK from 6 April.
Read moreFriday broker round-up
5th Mar 2021 13:07
(Sharecast News) - Aggreko: Peel Hunt upgrades to hold with a target price of 880p.
Read moreTuesday broker round-up
23rd Feb 2021 13:39
(Sharecast News) - Clinigen: Liberum reiterates buy with a target price of 1,050p.
Read moreMonday broker round-up
1st Feb 2021 13:44
(Sharecast News) - Polymetal International: Berenberg reiterates buy with a target price of 2,310p.
Read moreClinigen trades in line despite ongoing Covid-19 impact
26th Nov 2020 09:18
(Sharecast News) - Pharmaceutical and services company Clinigen said on Thursday that trading had been in-line with market expectations despite the ongoing impact of the Covid-19 pandemic.
Read moreMonday broker round-up
23rd Nov 2020 13:28
(Sharecast News) - DWF Group: Liberum initiates at hold with a target price of 90p.
Read moreTuesday broker round-up
10th Nov 2020 13:17
(Sharecast News) - On the Beach: Citigroup downgrades to neutral with a target price of 370p.
Read moreThursday broker round-up
23rd Jul 2020 14:25
(Sharecast News) - Stagecoach Group: Peel Hunt upgrades to buy with a target price of 70.0p.
Read moreClinigen FY revenues continue to rise, profit growth slowed by Covid-19
14th Jul 2020 09:07
(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.
Read moreClinigen gets orphan drug designation for 'aldesleukin' in the US
13th Jul 2020 16:29
(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for 'aldesleukin', in the treatment of amyotrophic lateral sclerosis (ALS).
Read moreMonday broker round-up
13th Jul 2020 13:48
(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p
Read moreSunday newspaper round-up: Two meters, Rolls Royce, Clinigen
14th Jun 2020 19:22
(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus infection and say it should not be used as evidence for relaxing the UK's 2-metre physical distancing rule. Critics of the distancing advice, which states that people should keep at least 2 metres apart, believe it is too cautious. They seized on the research commissioned by the WHO, which suggested a reduction from 2 metres to 1 would raise infection risk only marginally, from 1.3% to 2.6%. - Guardian
Read moreThursday broker round-up
28th May 2020 13:34
(Sharecast News) - Provident Financial: RBC Capital Markets reiterates sector performer with a target price of 195p.
Read more